Table 3.
Liraglutide (Victoza®) studies—CV outcomes.
| Study | N | Background OAD | Comparator | A1C reduction with liraglutide (%) | Change in body weight (kg) | Change in SBP (mmHg) | Change in DBP (mmHg) | Change in pulse rate (bpm) | Change in Tchol (mg/dL) | Change in LDL (mg/dL) | Change in TG (mg/dL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LEAD-1 [42,50] | 1041 | SU | TZD or placebo | −1.1 | −0.2* | −2.8 | −1.4 | +2 to +4* | NA | NA | NA |
| LEAD-2 [42,51] | 1091 | MET | SU or placebo | −1.0 | −2.8* | −2.3* | None | +2 to +3* | NA | NA | NA |
| LEAD-3 [42,52] | 746 | None | SU | −1.14 | −2.5* | −3.6* | None | +1.6 | NA | NA | NA |
| LEAD-4 [42,53] | 533 | MET+TZD | Placebo | −1.5 | −2.0* | −5.6* | −1.9 | +3* | −7.72 | −8.88 | −28.31 |
| LEAD-5 [42,54] | 581 | MET+SU | Insulin glargine or placebo | −1.33 | −1.8* | −4.0* | None | +2.62* | NA | NA | NA |
| LEAD-6 [7,42] | 464 | MET+SU | Exenatide | −1.12 | −3.2 | −2.5 | −1.05 | +3.28* | −7.72 | −16.98 | −36.28 |
Reference: LEAD 1–LEAD 6, Mundil et al.
*
Statistically significant compared with comparator drug.
SU, sulfonylurea; MET, metformin; TZD, thiazolidinedione.